News
In the phase 2/3 REFRαME-O1 trial, luveltamab tazevibulin showed encouraging responses in patients with ovarian cancer with ...
Samuraciclib improved progression-free survival in HR+ advanced breast cancer patients without TP53 mutations or liver ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback